Skip to main content
Erschienen in:

07.12.2018 | Original Article

Matrix Metalloproteinase-2 Single Nucleotide Polymorphism in Egyptian Non-Hodgkin Lymphoma Patients: Correlation with Clinicopathological Characteristics and Outcome

verfasst von: Rania M. Bakry, Ebtesam M. El-Gezawy, Abeer M. Darwish, Eman NasrEldin, Noha Gaber, Khalid A. Nasif, EssamAbd El-Mohsen, Salma Mahfouz

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Non-Hodgkin’s lymphoma (NHL) is an exceedingly diversified group of lymphoproliferative neoplasms emerging from B-, T- or natural killer -lymphocytes. This study was done to detect Matrix metalloproteinase-2 (MMP2)-735C/T gene polymorphism in patients with NHL and its relation to the clinicopathological characteristics of the studied patients in addition to detection the association between it and NHL disease susceptibility and progression. Clinico-hematological profiles were done on 50 NHL patients. The genotypes and allelic frequencies of MMP-2 polymorphisms were recognized utilizing Polymerase Chain Reaction–Restriction Fragment Length Polymorphism (PCR–RFLP). PCR products after adding restriction endonuclease were analyzed using QIAxcel advanced (automated) instrument. The CT + TT genotypes and T allele of MMP2 735C/T were statistically significant in patients having advanced clinical stages III/IV compared to patients with stages I/II. Another significance was observed in patients with intermediate high/high IPI score and BM infiltration. Interestingly, patients with MMP2-735C/T genotype exhibit lower rate of survival. Our results demonstrated that MMP2-735C/T polymorphism may potentially affect the progression of NHL. Further larger scale studies are needed.
Literatur
2.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, (2002). CA Cancer J Clin 55:74–108CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, (2002). CA Cancer J Clin 55:74–108CrossRefPubMed
3.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F GLOBOCAN (2012) v1.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, IARC, 2013 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F GLOBOCAN (2012) v1.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, IARC, 2013
4.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11–30CrossRef Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11–30CrossRef
5.
Zurück zum Zitat Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. (eds) (2007) Cancer incidence in five continents, vol IX. IARC Scientific Publication No. 160. http://gco.iarc.fr Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. (eds) (2007) Cancer incidence in five continents, vol IX. IARC Scientific Publication No. 160. http://​gco.​iarc.​fr
6.
Zurück zum Zitat Herzog CM, Dey S, Hablas A, Khaled HM, Seifeldin IA, Ramadan M, El-Hamzawy H, Wilson ML, Soliman AS (2012) Geographic distribution of hematopoietic cancers in the Nile delta of Egypt. Ann Oncol 23:2748–2755CrossRefPubMedPubMedCentral Herzog CM, Dey S, Hablas A, Khaled HM, Seifeldin IA, Ramadan M, El-Hamzawy H, Wilson ML, Soliman AS (2012) Geographic distribution of hematopoietic cancers in the Nile delta of Egypt. Ann Oncol 23:2748–2755CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics, 2014: Cancer Treatment and Survivorship Statistics, 2014. CA A Cancer J Clin 64:252–271CrossRef DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics, 2014: Cancer Treatment and Survivorship Statistics, 2014. CA A Cancer J Clin 64:252–271CrossRef
8.
Zurück zum Zitat Hadler-Olsen E, Winberg JO, Uhlin-Hansen L (2013) Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. TumourBiol 34:2041–2051 Hadler-Olsen E, Winberg JO, Uhlin-Hansen L (2013) Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. TumourBiol 34:2041–2051
9.
Zurück zum Zitat Butler GS, Overall CM (2009) Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov 8:935–948CrossRefPubMed Butler GS, Overall CM (2009) Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov 8:935–948CrossRefPubMed
10.
Zurück zum Zitat Yu C, Zhou Y, Miao X et al (2004) Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64:7622–7628CrossRefPubMed Yu C, Zhou Y, Miao X et al (2004) Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64:7622–7628CrossRefPubMed
11.
Zurück zum Zitat Sag SO, Gorukmez O, Ture M, Gorukmez O, Topak A, Sahinturk S, Ocakoglu G, Gulten T, Ali R, Yakut T (2015) MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms in JAK2V617F positive myeloproliferative disorders. Asian Pac J Cancer Prev 16:443–449CrossRefPubMed Sag SO, Gorukmez O, Ture M, Gorukmez O, Topak A, Sahinturk S, Ocakoglu G, Gulten T, Ali R, Yakut T (2015) MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms in JAK2V617F positive myeloproliferative disorders. Asian Pac J Cancer Prev 16:443–449CrossRefPubMed
12.
Zurück zum Zitat Cauwe B, Van den Steen PE, Opdenakker G (2007) The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 42:113–185CrossRefPubMed Cauwe B, Van den Steen PE, Opdenakker G (2007) The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 42:113–185CrossRefPubMed
13.
Zurück zum Zitat Shen W, Xi H, Wei B, Chen L (2014) The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis. J Cancer Res Clin Oncol 140:1003–1009CrossRefPubMed Shen W, Xi H, Wei B, Chen L (2014) The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis. J Cancer Res Clin Oncol 140:1003–1009CrossRefPubMed
14.
Zurück zum Zitat Jezierska A, Motyl T (2009) Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 15:Ra32–Ra40PubMed Jezierska A, Motyl T (2009) Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 15:Ra32–Ra40PubMed
15.
Zurück zum Zitat Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y et al (2010) The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest 28:661–669CrossRefPubMed Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y et al (2010) The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest 28:661–669CrossRefPubMed
16.
Zurück zum Zitat Van der Jagt MF, Wobbes T, Strobbe LJ, Sweep FC, Span PN (2010) Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol 101:259–269PubMed Van der Jagt MF, Wobbes T, Strobbe LJ, Sweep FC, Span PN (2010) Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol 101:259–269PubMed
17.
Zurück zum Zitat Gadducci A, Cosio S, Tana R, Genazzani AR (2009) Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 69:12–27CrossRefPubMed Gadducci A, Cosio S, Tana R, Genazzani AR (2009) Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 69:12–27CrossRefPubMed
18.
Zurück zum Zitat Travaglino E, Benatti C, Malcovati L et al (2008) Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur J Haematol 80:216–226CrossRefPubMed Travaglino E, Benatti C, Malcovati L et al (2008) Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur J Haematol 80:216–226CrossRefPubMed
19.
Zurück zum Zitat Buggins AG, Levi A, Gohil S et al (2011) Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 154:216–222CrossRefPubMed Buggins AG, Levi A, Gohil S et al (2011) Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 154:216–222CrossRefPubMed
20.
Zurück zum Zitat Kuittinen O, Savolainen ER, Koistinen P, Möttönen M, Turpeenniemi-Hujanen T (2001) MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk Res 25:125–131CrossRefPubMed Kuittinen O, Savolainen ER, Koistinen P, Möttönen M, Turpeenniemi-Hujanen T (2001) MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk Res 25:125–131CrossRefPubMed
21.
Zurück zum Zitat Diao LP, Ma H, Wei GC, Li T, Liu HS, Liu LH, Wu LL, Zhao GM, Gao YH (2012) Matrix metalloproteinase-2 promoter and tissue inhibitor of metalloproteinase-2 gene polymorphisms in non-Hodgkin’s lymphoma. Int J Cancer 131(5):1095–1103CrossRefPubMed Diao LP, Ma H, Wei GC, Li T, Liu HS, Liu LH, Wu LL, Zhao GM, Gao YH (2012) Matrix metalloproteinase-2 promoter and tissue inhibitor of metalloproteinase-2 gene polymorphisms in non-Hodgkin’s lymphoma. Int J Cancer 131(5):1095–1103CrossRefPubMed
22.
Zurück zum Zitat Gouda HM, Khorshied MM, El Sissy MH, Shaheen IAM, Mohsen MMA (2014) Association between matrix metalloproteinase 2 (MMP2) promoter polymorphisms and the susceptibility to non-Hodgkin’s lymphoma in Egyptians. Ann Hematol 93:1313–1318PubMed Gouda HM, Khorshied MM, El Sissy MH, Shaheen IAM, Mohsen MMA (2014) Association between matrix metalloproteinase 2 (MMP2) promoter polymorphisms and the susceptibility to non-Hodgkin’s lymphoma in Egyptians. Ann Hematol 93:1313–1318PubMed
23.
Zurück zum Zitat Vasku A, Vasku JB, Necas M, Vasku V (2010) Matrix Metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage. J Biomed Biotechnol 2010:805907CrossRefPubMedPubMedCentral Vasku A, Vasku JB, Necas M, Vasku V (2010) Matrix Metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage. J Biomed Biotechnol 2010:805907CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, Zhang X, Xiong P, Lin D (2005) Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancersusceptibility. Carcinogenesis 26:1117–1121CrossRefPubMed Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, Zhang X, Xiong P, Lin D (2005) Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancersusceptibility. Carcinogenesis 26:1117–1121CrossRefPubMed
25.
Zurück zum Zitat Rollin J, Régina S, Vourc’h P, Iochmann S, Bléchet C, Reverdiau P, Gruel Y (2007) Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 56:273–280CrossRefPubMed Rollin J, Régina S, Vourc’h P, Iochmann S, Bléchet C, Reverdiau P, Gruel Y (2007) Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 56:273–280CrossRefPubMed
26.
Zurück zum Zitat Miao X, Yu C, Tan W, Xiong P, Liang G, Lu W, Lin D (2003) A functional polymorphism in the matrix metalloproteinase-2 gene promoter (− 1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 63:3987–3990PubMed Miao X, Yu C, Tan W, Xiong P, Liang G, Lu W, Lin D (2003) A functional polymorphism in the matrix metalloproteinase-2 gene promoter (− 1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 63:3987–3990PubMed
27.
Zurück zum Zitat Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, Scorza R (2002) A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 8:3820–3823PubMed Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, Scorza R (2002) A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 8:3820–3823PubMed
28.
Zurück zum Zitat Kelly T, Borset M, Abe E et al (2000) Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma 37(3–4):273–281CrossRefPubMed Kelly T, Borset M, Abe E et al (2000) Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma 37(3–4):273–281CrossRefPubMed
29.
Zurück zum Zitat Thomas KH, Myen P, Suttorp N (2006) Single nucleotide polymorphismin 5′-flankingregion reduces transcription of surfactant protein B gene in H441 cells. Am J Physiol Lung Cell Mol Physiol 291(3):L386–L390CrossRefPubMed Thomas KH, Myen P, Suttorp N (2006) Single nucleotide polymorphismin 5′-flankingregion reduces transcription of surfactant protein B gene in H441 cells. Am J Physiol Lung Cell Mol Physiol 291(3):L386–L390CrossRefPubMed
30.
Zurück zum Zitat Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM (1995) C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol 15(1):58–64CrossRefPubMed Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM (1995) C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol 15(1):58–64CrossRefPubMed
Metadaten
Titel
Matrix Metalloproteinase-2 Single Nucleotide Polymorphism in Egyptian Non-Hodgkin Lymphoma Patients: Correlation with Clinicopathological Characteristics and Outcome
verfasst von
Rania M. Bakry
Ebtesam M. El-Gezawy
Abeer M. Darwish
Eman NasrEldin
Noha Gaber
Khalid A. Nasif
EssamAbd El-Mohsen
Salma Mahfouz
Publikationsdatum
07.12.2018
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 3/2019
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-1056-4

Neu im Fachgebiet Onkologie

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Bei Achalasie auf Candidiasis der Speiseröhre achten!

Bei Achalasie-Betroffenen sollte man immer auch auf Candida-Infektionen achten, warnen Forschende aus Rotterdam. In ihrer Studie ließ die Pilzinfektion das Risiko für ein Ösophaguskarzinom massiv steigen.

Adipositas als negativer Prognosefaktor bei Kindern mit Krebs

Eine kanadische Studie weist darauf hin, dass Übergewicht zum Zeitpunkt der Krebsdiagnose ein unabhängiger Risikofaktor für schlechtere Überlebenschancen bei erkrankten Kindern und Jugendlichen sein könnte. Allerdings sind nicht alle Patientinnen und Patienten gleichermaßen betroffen.


Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.